Harmony Biosciences Holdings, Inc. reiterated revenue guidance for the year 2024. For the period, the company expects net product revenue of $700 million to $720 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.72 USD | +2.38% | -1.65% | -7.99% |
30/04 | Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise | MT |
30/04 | Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.99% | 1.69B | |
+34.35% | 705B | |
+30.63% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+14.73% | 238B | |
-3.35% | 210B | |
+10.39% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- HRMY Stock
- News Harmony Biosciences Holdings, Inc.
- Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024